SESN2 and hepatocellular carcinoma: The promising systemic agent sorafenib merely demonstrated limited benefits to about 30% HCC patients since some patients are initially resistant to sorafenib.27 To testify the potential involvement of SESN2 in sorafenib therapeutic response, we first examined sorafenib IC50 of HCC cell lines including Bel‐7404, HLF, HLE, SNU‐368, and Hep3B by culturing them with 0, 2, 5, 10, 15, 20, and 25 μmol/L sorafenib, respectively, for 24 hours and then using CCK‐8 assay to examine cell viability.